DDI-MedLine.d193.s0 >> Ticagrelor (Brilinta)--better than clopidogrel (Plavix) >> 0-9,12-19,35-45,48-53
DDI-MedLine.d193.s1 >> The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). >> 21-30,33-40,64-80,105-111
DDI-MedLine.d193.s2 >> It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. >> 21-31,34-39,46-54,57-63
DDI-MedLine.d193.s3 >> Clopidogrel is expected to become available generically in the US within the next few months. >> 0-10
